Todas las investigaciones
Activo, no reclutandoFASE2INTERVENCIONISTA

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

This study is a clinical trial looking at a new medicine called volixibat. It's for people who have a liver condition called Primary Sclerosing Cholangitis (PSC) and are troubled by itching. Researchers want to find out if volixibat is safe and if it can help reduce this itching. They also want to understand if the medicine might have an effect on the overall progression of PSC. Patients in the study will either receive volixibat or a dummy medicine (placebo). This research is currently in Phase 2, which means it’s still an early stage where doctors are mainly checking for safety and how well the medicine works.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE2
Patrocinador
Mirum Pharmaceuticals, Inc.
Objetivo de inscripción
182
Inicio
18 dic 2020
Estimación de finalización
01 Mar 2028

¿De qué trata este estudio?

This clinical trial is all about a new investigational medicine called volixibat. Doctors are studying it because they want to find better ways to help people who have a liver condition called Primary Sclerosing Cholangitis, or PSC, especially if they experience persistent and bothersome itching. PSC is a chronic disease that affects the bile ducts in the liver. These ducts can become inflamed and scarred, which can lead to various symptoms, including severe itching. The research team wants to see if volixibat can ease this itching for people with PSC. They will also be looking to see if the medicine has any impact on how the disease develops over time, which is very important for people living with PSC. In this study, some participants will receive the investigational medicine, volixibat, while others will receive a placebo. A placebo is a dummy treatment that looks just like the real medicine but contains no active ingredients. This helps researchers to fairly compare the effects of volixibat. This is a Phase 2 study, which means it's an important step where the medicine's safety and effectiveness are being carefully evaluated.

Puntos clave

  • This study is testing a new medicine, volixibat, for itching related to PSC.
  • It aims to see if volixibat is safe and effective for this type of itching.
  • The study also looks at how the medicine might affect PSC progression.
  • Some participants will receive the active medicine; others will receive a placebo.
  • It's a Phase 2 study, focusing on early safety and effectiveness.
  • Your participation is voluntary, and you can withdraw at any time.

¿Quién puede ser elegible?

To join this study, you would need to be at least 12 years old if you live in certain areas, or 18 years old in others. You must have a confirmed diagnosis of PSC and be experiencing bothersome itching because of it. If you're already taking medicines for PSC or to help with itching, or if you also have Inflammatory Bowel Disease (IBD), you might still be able to join under certain conditions.

However, some things would prevent you from taking part. For example, if your itching is caused by something other than PSC, or if you have severe liver problems or a history of certain surgeries that affect your digestive system, you wouldn't be able to join. Also, if you've recently had certain procedures on your bile ducts or if some of your blood test results are outside a specific range, you might not be eligible.

It's important that you understand and agree to all the study requirements, including attending all visits and follow-up appointments.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I have been diagnosed with Primary Sclerosing Cholangitis (PSC).
  2. I experience bothersome itching because of my PSC.
  3. I am at least 12 years old (or 18, depending on location).
  4. I am generally in stable health and don't have very severe liver problems.
  5. I am willing and able to attend all study appointments and follow instructions.
  6. I haven't had recent surgery that affected my digestive system in a major way.
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in this study, you will first have screening appointments to make sure you meet all the requirements. Throughout the study, you'll have regular visits to the clinic where doctors will monitor your health, check for any changes in your itching, and take blood samples. You will be given either the study medicine, volixibat, or a placebo, and you'll need to take it as instructed. There will also be follow-up appointments after you stop taking the study medicine to ensure your well-being. The total duration of your involvement in the study, including follow-up, will be explained in detail by the study team.

Riesgos y beneficios potenciales

Participating in this study might offer potential benefits, such as gaining access to a new investigational medicine that could help reduce your itching from PSC. You'd also be contributing valuable information that could help others with PSC in the future. However, there are potential risks, as with any new medicine. Volixibat might cause side effects, and these will be carefully explained to you. You'll receive close medical monitoring throughout the study. Remember, joining is entirely voluntary, and you have the right to withdraw from the study at any time without affecting your medical care.

Locations (103)

  • Southern California Research Center
    Código postal verificado
    Coronado, United States
  • Cedars Sinai Medical Center
    Código postal verificado
    Los Angeles, United States
  • University of California, Davis
    Código postal verificado
    Sacramento, United States
  • California Pacific Medical Center Research Institute
    Código postal verificado
    San Francisco, Estados Unidos
  • University of Colorado - Anschutz Medical Campus
    Código postal verificado
    Aurora, Estados Unidos
  • MedStar Georgetown University Hospital
    Código postal verificado
    Washington D.C., Estados Unidos
  • Florida Research Institute
    Código postal verificado
    Lakewood Rch, United States
  • University of Miami - Schiff Center for Liver Diseases
    Código postal verificado
    Miami, United States
  • Tampa General Hospital
    Código postal verificado
    Tampa, Estados Unidos
  • Beth Israel Deaconess Medical Center
    Código postal verificado
    Boston, Estados Unidos
  • Henry Ford Hospital
    Código postal verificado
    Detroit, Estados Unidos
  • Mayo Clinic
    Código postal verificado
    Rochester, United States

Preguntas comunes

What is PSC?

PSC, or Primary Sclerosing Cholangitis, is a long-term liver disease where the bile ducts gradually become inflamed and scarred, which can lead to symptoms like itching.

What is volixibat?

Volixibat is an investigational medicine being tested in this study to see if it can help reduce itching in people with PSC and affect how the disease progresses.

¿Qué es un placebo?

A placebo is a 'dummy' medicine that looks like the real thing but doesn't contain any active drug. It's used in studies to compare the effects of the actual medicine fairly.

¿Sabré si estoy recibiendo el medicamento real o el placebo?

No, during the main part of the study, neither you nor your doctors will know whether you are receiving volixibat or the placebo. This is to ensure the study results are unbiased.

What 'phase' is this study?

This is a Phase 2 study. This means it's an early stage where doctors are mainly checking for the medicine's safety and how well it works.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.